{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:22:01Z","timestamp":1759940521339,"version":"3.38.0"},"reference-count":55,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p> Objective: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results: Ten ( n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion: It was possible to generate evidence about the safety profile of different ADHD drugs. <\/jats:p>","DOI":"10.1177\/1087054717696773","type":"journal-article","created":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T07:28:41Z","timestamp":1491204521000},"page":"111-120","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses"],"prefix":"10.1177","volume":"23","author":[{"given":"Danielly","family":"Chierrito de Oliveira","sequence":"first","affiliation":[{"name":"Universidade Estadual do Oeste do Paran\u00e1, Cascavel, Brazil"}]},{"given":"Patricia","family":"Guerrero de Sousa","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Oeste do Paran\u00e1, Cascavel, Brazil"}]},{"given":"Camila","family":"Borges dos Reis","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Oeste do Paran\u00e1, Cascavel, Brazil"}]},{"given":"Fernanda Stumpf","family":"Tonin","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Curitiba, Brazil"}]},{"given":"Laiza","family":"Maria Steimbach","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Curitiba, Brazil"}]},{"given":"Suzane","family":"Virtuoso","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Oeste do Paran\u00e1, Cascavel, Brazil"}]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[{"name":"Universidade de Lisboa, Lisboa, Portugal"}]},{"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Universidade Federal do Paran\u00e1, Curitiba, Brazil"}]},{"given":"Andr\u00e9ia","family":"Cristina Conegero Sanches","sequence":"additional","affiliation":[{"name":"Universidade Estadual do Oeste do Paran\u00e1, Cascavel, Brazil"}]}],"member":"179","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"bibr1-1087054717696773","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m08144"},{"key":"bibr2-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318192e4a0"},{"key":"bibr3-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181a390ce"},{"key":"bibr4-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2014.04.008"},{"key":"bibr5-1087054717696773","unstructured":"American Psychiatry Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. Retrieved from https:\/\/psicovalero.files.wordpress.com\/2014\/06\/dsm-v-manual-diagnc3b3stico-y-estadc3adstico-de-los-trastornos-mentales.pdf"},{"key":"bibr6-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1274"},{"key":"bibr7-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1177\/1087054712441969"},{"key":"bibr8-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113519509"},{"key":"bibr9-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116636105"},{"key":"bibr10-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2015.12.017"},{"key":"bibr11-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(02)00346-9"},{"key":"bibr12-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.08.025"},{"key":"bibr13-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0074-2"},{"key":"bibr14-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114560183"},{"key":"bibr15-1087054717696773","unstructured":"Canadian Agency for Drugs and Technologies in Health. (2016). Rapid response report\u2014Summary with critical appraisal: Pharmacologic management of patients with ADHD: A review of guidelines. Retrieved from https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/htis\/mar-2016\/RC0759%20ADHD%20Management%20Final.pdf"},{"key":"bibr16-1087054717696773","unstructured":"Canadian Attention Deficit Hyperactivitiy Disorder Resource Alliance. (2011). Canadian ADHD Practice guidelines (CAP) guidelines (3rd ed.). Toronto, Ontario: Author. Retrieved from http:\/\/www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011.pdf"},{"key":"bibr17-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5453"},{"key":"bibr18-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.06.032"},{"key":"bibr19-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"bibr20-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199709000-00033"},{"key":"bibr21-1087054717696773","doi-asserted-by":"crossref","unstructured":"Evans D. (2003). Hierarchy of evidence: A framework for ranking evidence evaluating healthcare interventions. Journal of Clinical Nursing, 12, 77-84. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12519253","DOI":"10.1046\/j.1365-2702.2003.00662.x"},{"key":"bibr22-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G582"},{"key":"bibr23-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1177\/1087054713510352"},{"key":"bibr24-1087054717696773","unstructured":"Hamedi M., Mohammadi M., Ghaleiha A., Keshavarzi Z., Jafarinia M., Keramatfar R. Akhondzadeh S. (2014). Bupropion in adults with attention-deficit\/hyperactivity disorder: A randomized, double-blind study. Acta Medica Iranica, 52, 675-680. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25325205"},{"key":"bibr25-1087054717696773","unstructured":"Higgins J. P. T., Green S. (2011). Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration. Available from http:\/\/handbook.cochrane.org\/"},{"key":"bibr26-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"bibr27-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00347.x"},{"key":"bibr28-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-159"},{"key":"bibr29-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.4.716"},{"key":"bibr30-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.124"},{"key":"bibr31-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.03.022"},{"key":"bibr32-1087054717696773","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m07767"},{"key":"bibr33-1087054717696773","doi-asserted-by":"crossref","unstructured":"Michelson D., Adler L., Spencer T., Reimherr F. W., West S. A., Allen A. J. Milton D. (2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112-120. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12547466","DOI":"10.1016\/S0006-3223(02)01671-2"},{"key":"bibr34-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1177\/108705479700200302"},{"key":"bibr35-1087054717696773","doi-asserted-by":"crossref","unstructured":"Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17, 1-12. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8721797","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"bibr36-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31815d9af7"},{"key":"bibr37-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1080\/j.1440-1614.1999.00590.x"},{"key":"bibr38-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1026"},{"key":"bibr39-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1158"},{"key":"bibr40-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-35552007000100013"},{"key":"bibr41-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.048827"},{"key":"bibr42-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.07.032"},{"key":"bibr43-1087054717696773","doi-asserted-by":"crossref","unstructured":"Spencer T. J., Adler L. A., Weisler R. H., Youcha S. H. (2008). Triple-bead mixed amplhetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. The Journal of Clinical Psychiatry, 69, 1437-1448. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19012813","DOI":"10.4088\/JCP.v69n0911"},{"key":"bibr44-1087054717696773","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp130638"},{"key":"bibr45-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.699"},{"key":"bibr46-1087054717696773","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.10m06788"},{"key":"bibr47-1087054717696773","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2013.868925"},{"key":"bibr48-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00238-X"},{"key":"bibr49-1087054717696773","doi-asserted-by":"crossref","unstructured":"Valkenhoef V. G., Tervonen T., Zwinkels T., Brock B., Hillege H. (2013). ADDIS: A decision support system for evidence-based medicine. Decision Support Systems, 55, 459-475. Retrieved from https:\/\/www.researchgate.net\/publication\/257016000_ADDIS_A_decision_support_system_for_evidence-based_medicine","DOI":"10.1016\/j.dss.2012.10.005"},{"key":"bibr50-1087054717696773","doi-asserted-by":"crossref","unstructured":"Viktrup L., Pangallo B. A., Detke M. J., Zinner N. R. (2004). Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. The Primary Care Companion to the Journal of Clinical Psychiatry, 6(2), 65-73. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC427601\/","DOI":"10.4088\/PCC.v06n0204"},{"key":"bibr51-1087054717696773","doi-asserted-by":"crossref","unstructured":"Weisler R. H., Biederman J., Spencer T. J., Wilens T. E., Faraone S. V., Chrisman A. K. Tulloch S. J. (2006). Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectrums, 11, 625-639. Retrieved from https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16871129","DOI":"10.1017\/S1092852900013687"},{"key":"bibr52-1087054717696773","doi-asserted-by":"publisher","DOI":"10.2165\/11631990-000000000-00000"},{"key":"bibr53-1087054717696773","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04785pur"},{"key":"bibr54-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.9.1147"},{"key":"bibr55-1087054717696773","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e31820c00eb"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087054717696773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1087054717696773","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1087054717696773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T06:46:44Z","timestamp":1740811604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1087054717696773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/1087054717696773"],"URL":"https:\/\/doi.org\/10.1177\/1087054717696773","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"type":"print","value":"1087-0547"},{"type":"electronic","value":"1557-1246"}],"subject":[],"published":{"date-parts":[[2017,4,3]]}}}